Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Combination chemotherapy in the treatment of advanced Hodgkin's disease.

× No keyword cloud information.

170 in total

1. [Morbus Hodgkin in autopsies today (author's transl)].

Authors: E Grundmann; R Fritzsche
Journal: Z Krebsforsch Klin Onkol Cancer Res Clin Oncol Date: 1975

2. [Heavy chain disease: humoral and cellular findings in six patients with mu chain disease (author's transl)].

Authors: O Wetter; C G Schmidt; K H Linder; W Leene
Journal: J Cancer Res Clin Oncol Date: 1979-06-08 Impact factor: 4.553

3. Hodgkin's Disease 1985.

Authors: R E Myers; J S Ginsberg
Journal: Can Fam Physician Date: 1985-06 Impact factor: 3.275

Review 4. Changing role and decreasing size: current trends in radiotherapy for Hodgkin's disease.

Authors: Joachim Yahalom
Journal: Curr Oncol Rep Date: 2002-09 Impact factor: 5.075

Review 5. [Hodgkin's disease. Results in diagnosis and treatment (author's transl)].

Authors: D Huhn; W Wilmanns
Journal: Klin Wochenschr Date: 1979-04-17

6. The NIH Clinical Center and the future of clinical research.

Authors: John I Gallin
Journal: Nat Med Date: 2011-10-11 Impact factor: 53.440

7. Fast neutron treatment for squamous cell carcinoma.

Authors:
Journal: BMJ Date: 1991-02-09

8. Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305).

Authors: Michinori Ogura; Kuniaki Itoh; Tomohiro Kinoshita; Haruhiko Fukuda; Takeaki Takenaka; Tomoko Ohtsu; Yoshitoyo Kagami; Kensei Tobinai; Masataka Okamoto; Hideki Asaoku; Tsuneo Sasaki; Chikara Mikuni; Masami Hirano; Takaaki Chou; Kazunori Ohnishi; Hitoshi Ohno; Kaori Nasu; Kenichi Okabe; Shuichi Ikeda; Shigeo Nakamura; Tomomitsu Hotta; Masanori Shimoyama
Journal: Int J Hematol Date: 2010-11-16 Impact factor: 2.490

Review 9. Balancing risks and benefits of therapy for patients with favorable-risk limited-stage Hodgkin lymphoma: the role of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy alone.

Authors: Annette E Hay; Ralph M Meyer
Journal: Hematol Oncol Clin North Am Date: 2014-02 Impact factor: 3.722

10. Immunity of Epstein-Barr virus in Hodgkin's disease preceded by infectious mononucleosis.

Authors: P R Band; P H Levine; V C Patwardhan; T K Shnitka; H F Pabst
Journal: Can Med Assoc J Date: 1973-01-20 Impact factor: 8.262